This study is the first to report that Wnt2 is significantly higher in BRAF-mutated CRC tissues than in wild-type tissues, which provides a new approach for exploring the development and treatment of patients with BRAF mutations. The gene discussed is BRAF; the disease is colorectal carcinoma.